Life Sciences News | BioTuesdays by Kilmer Lucas IR

Markets

BTIG assumes coverage of Bionano Genomics at buy; PT $3.50

BTIG analyst Mark Massaro assumed coverage of Bionano Genomics (NASDAQ:BNGO) with a “buy” rating and price target of $3.50. The stock closed at $2.16 on Dec. 9. Bionano provides optical genome mapping technology tools...

December 12, 2022

Developments

UT Southwestern performs 100th procedure with Profound’s TULSA-PRO

UT Southwestern in Dallas, one of the nation’s premier academic medical centers, performed its 100th procedure with Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO, an innovative MRI-guided minimally invasive...

December 9, 2022

Markets

HCW starts Enanta Pharma at buy; PT $56

H.C. Wainwright initiated coverage of Enanta Pharmaceuticals (NASDAQ:ENTA) with a “buy” rating and $56 price target. The stock closed at $41.78 on Dec. 8. Enanta’s claim to fame is the discovery of glecaprevir...

December 9, 2022

Developments

Context posts encouraging preliminary Phase 2 data in breast cancer

Context Therapeutics (NASDAQ:CNTX) reported preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s orally administered progesterone receptor (PR) antagonist, in...

December 8, 2022

Markets

Maxim ups NLS Pharma to buy on funding from BVF Partners

Maxim Group upgraded NLS Pharmaceuticals (NASDAQ:NLSP) to “buy” from “hold” with a new $4 price target. The stock closed at 88 cents on Dec. 7 when NLS announced a purchase agreement with BVF Partners, a leading...

December 8, 2022

Markets

HCW starts Opthea at buy; PT $14

H.C. Wainwright launched coverage of Opthea (NASDAQ:OPT) with a “buy” rating and $14 price target. The stock closed at $4.97 on Dec. 7. Opthea is focused on patients suffering from retinal eye diseases, such as wet age...

December 8, 2022

Markets

Maxim starts Blue Water Vaccines at buy; PT $4

Maxim Group initiated coverage of Blue Water Vaccines (NASDAQ:BWV) with a “buy” rating and price target of $4. The stock closed at $1.15 on Dec. 7. Blue Water is developing a portfolio of vaccine candidates targeting...

December 8, 2022

Developments

Rani posts positive repeat-dose results with RaniPill in osteoporosis

Rani Therapeutics (NASDAQ:RANI) reported topline results from the repeat-dose Part 2 of a Phase 1 study of RT-102, the RaniPill GO capsule containing a proprietary formulation of human parathyroid hormone being...

December 7, 2022

Developments

IntelGenx, UPEI collaborate on VetaFilm platform in dogs and cats

IntelGenx (TSX:IGX; OTCQB:IGXT) and the University of Prince Edward Island are collaborating on a research project to assess palatability, owner-perceived acceptability, and ease of administration of IntelGenx’s...

December 7, 2022

Markets

BTIG ups Aerovate to buy on competitor data

BTIG upgraded Aerovate Therapeutics (NASDAQ:AVTE) to “buy” from “neutral” with a $27 price target, citing Gossamer Bio’s TORREY results that could validate Aerovate’s dry powder inhalation (DPI) administered tyrosine...

December 6, 2022

Developments

FDA fast tracks Vistagen’s PH10 for major depressive disorder

The FDA granted Vistagen (NASDAQ:VTGN) fast track designation for development of PH10, an investigational nasal sprays, for the treatment of major depressive disorder (MDD). The FDA decision aligns with “our belief in...

December 6, 2022

Developments

Hepion completes enrollment early in Phase 2 ALTITUDE-NASH liver function trial

Hepion Pharmaceuticals (NASDAQ:HEPA) completed enrollment of 60 non-alcoholic steatohepatitis (NASH) stage 3 (F3) subjects in the Phase 2 ALTITUDE-NASH clinical trial. The trial is being conducted in collaboration with...

December 5, 2022

Subscribe